It is unclear how the mutation in CYP2D6 could impact clinical outcome after NACT in patients with ovarian cancer, as carboplatin is excreted primarily by kidneys and paclitaxel is metabolized mainly by cytochromes P450 2C8 and 3A4 [21]. The gene discussed is CYP2C8; the disease is ovarian carcinoma.